41994-92-7

Basic information

• Product Name: 5-METHOXY-2-NITROBENZAMIDE
• Synonyms: 5-METHOXY-2-NITROBENZAMIDE
• CAS NO: 41994-92-7
• Molecular Formula: C₈H₈N₂O₄
• Molecular Weight: 196.16
• Product Categories: Anilines, Amides & Amines;Anisoles, Alkyloxy Compounds & Phenylacetates;Nitro Compounds
• Mol File: 41994-92-7.mol
• Article Data: 16

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-METHOXY-2-NITROBENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHOXY-2-NITROBENZAMIDE(41994-92-7)
• EPA Substance Registry System: 5-METHOXY-2-NITROBENZAMIDE(41994-92-7)

Safety Data

• Hazardous Substances Data: 41994-92-7(Hazardous Substances Data)

Upstream product

• 63932-00-3 5-methoxy-2-nitrobenzoyl chloride 
• 1882-69-5 5-methoxy-2-nitro-benzoic acid 

Downstream Products

• 1882-71-9 2-amino-5-methoxybenzamide 
• 32618-84-1 6-Methoxyquinazolin-2,4-dione 
• 38469-84-0 2-nitro-5-methoxybenzonitrile 
• 1448462-26-7 (E)-5-methoxy-2-(3-(2-methoxyphenyl)acrylamido)benzamide 
• 1448462-36-9 5-methoxy-2-(3-phenylpropanamido)benzamide 
• 1448462-21-2 2-cinnamamido-5-methoxybenzamide 
• 869298-93-1 ethyl ((2-(aminocarbonyl)-4-methoxyphenyl)amino)(oxo)acetate 
• 371946-32-6 6-hydroxy-2-(3-nitrophenyl)quinazolin-4(3H)-one 
• 371947-63-6 2-(3-nitrophenyl)-4-oxo-3,4-dihydroquinazolin-6-yl acetate 

Relevant articles and documents

Anthranilamide-based 2-phenylcyclopropane-1-carboxamides, 1,1'-biphenyl-4-carboxamides and 1,1'-biphenyl-2-carboxamides: Synthesis biological evaluation and mechanism of action

Several anthranilamide-based 2-phenylcyclopropane-1-carboxamides 13a-f, 1,1’-biphenyl-4-carboxamides 14a-f and 1,1’-biphenyl-2-carboxamides 17a-f were obtained by a multistep procedure starting from the (1S,2S)-2-phenylcyclopropane-1-carbonyl chloride 11, the 1,1'-biphenyl-4-carbonyl chloride 12 or the 1,1'-biphenyl-2-carbonyl chloride 16 with the appropriate anthranilamide derivative 10a-f. Derivatives 13a-f, 14a-f and 17a-f showed antiproliferative activity against human leukemia K562?cells. Among these derivatives 13b, 14b and 17b exerted a particular cytotoxic effect on tumor cells. Derivative 17b showed a better antitumoral effect on K562?cells than 13b and 14b. Analyses performed to explore 17b mode of action revealed that it induced an arrest in G2/M phase of cell cycle which was consequent to DNA lesions as demonstrated by the increase in phospho-ATM and γH2AX, two known markers of DNA repair response system. The effect of 17b was also related to ROS generation, activation of JNK and induction of caspase-3 dependent apoptosis.

SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS

The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen containing heterocycle, ring B is an optionally substituted monocyclic homocycle or an optionally substituted monocyclic heterocycle, Z is N or NR1 (R1 is a hydrogen atom or an optionally substituted hydrocarbon group), is a single bond or a double bond, R2 is a hydrogen atom or an optionally substituted hydrocarbon group, X is an optionally substituted spacer having 1 to 6 atoms, ring C is (1) an optionally substituted homocycle or (2) an optionally substituted heterocycle other than a ring represented by (II) (X′ is S, O, SO, or CH2), and at least one of ring B and ring C has substituent(s), provided that N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]2 hydroxypropyl}5,6 dimethyl 4 oxo 1,4 dihydrothieno[2,3-d]pyrimidine-2-carboxamide is excluded, or a salt thereof.

2-Cinnamamido, 2-(3-phenylpropiolamido), and 2-(3-phenylpropanamido) benzamides: Synthesis, antiproliferativeactivity, and mechanism of action

Several new benzamides 4a-q were synthesized by stirring in pyridine the acid chlorides 3a-q with the appropriate anthranilamide derivatives 2a-g. Some of the synthesized compounds were evaluated for their in vitro antiproliferative activity against a panel of 5 human cell lines (K562 human chronic myelogenous leukemia cells, MCF-7 breast cancer cells, HTC-116 and HT26 colon cancer cells and NCI H460 non-small cell lung cancer cells).